HLA markers provide the tissue-specific comparison used to evaluate donor and recipient compatibility. Histocompatibility testing examines these markers on both individuals, allowing clinical teams to identify immunologic differences that may affect donor selection. This information is particularly important when comparing multiple potential donors, because the results contribute to decisions intended to reduce rejection risk and support graft survival.
Antibody screening evaluates whether the recipient has antibodies capable of recognizing donor cells, adding an immune-response perspective to the HLA comparison. Tissue typing describes the markers present, whereas screening identifies potentially relevant recipient antibodies. Considering both types of information helps clinicians recognize incompatibilities that might not be apparent from marker comparison alone and supports safer transplant planning.
Crossmatching provides a direct compatibility assessment between recipient antibodies and donor cells. When the results indicate recognition, clinicians can identify a potential antibody-mediated concern before transplantation rather than relying only on separate donor and recipient evaluations. Used alongside tissue typing and antibody screening, crossmatching strengthens the immunologic assessment that guides donor selection and clinical decision-making.
A typical evaluation combines tissue typing, antibody screening, and crossmatching. Tissue typing compares donor and recipient HLA markers, antibody screening looks for recipient antibodies relevant to donor recognition, and crossmatching assesses the interaction between the recipient and donor samples. Together, these complementary results provide the compatibility information needed before a transplant is considered.
These studies are used when clinicians evaluate potential donors for organ, tissue, or hematopoietic stem cell transplantation. The testing helps compare candidates and identify immunologic concerns before the procedure. Because the same general principles apply across several transplant settings, histocompatibility results can support donor selection in different clinical contexts rather than serving only one type of graft.
Histocompatibility results can help identify patients who may face antibody-mediated complications, making them relevant beyond the initial donor-selection decision. The findings inform clinical decisions before transplantation and can also support monitoring when immune incompatibility is a concern. By recognizing these risks, clinicians can interpret the patient’s transplant course in relation to potential rejection and graft-survival challenges.